Cargando…
Corrigendum to “Does ivermectin have a place in the treatment of mild Covid-19?” [New Microbes New Infect 46 (C) (2022 Mar) 100985]
Autor principal: | Schwartz, Eli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247222/ https://www.ncbi.nlm.nih.gov/pubmed/35791412 http://dx.doi.org/10.1016/j.nmni.2022.101000 |
Ejemplares similares
-
Does ivermectin have a place in the treatment of mild Covid-19?
por: Schwartz, Eli
Publicado: (2022) -
Corrigendum to “The global threat of antimicrobial resistance: science for intervention” [New Microbes New Infect 6 (2015): 22–29]
por: Roca, I., et al.
Publicado: (2015) -
Corrigendum to “First detection of Aspergillus fumigatus azole resistant strain due to Cyp51A TR46/Y121F/T289A in an azole-naive patient in Spain” [New Microbes New Infect 6 (2015) 33–34]
por: Pelaez, T., et al.
Publicado: (2016) -
Corrigendum to ‘Noncontiguous finished genome sequence and description of Bartonella mastomydis sp. nov.’ [New Microbes New Infect 25 (2018) 60–70]
por: Dahmani, M., et al.
Publicado: (2018) -
Corrigendum to: 2022 WCoP Abstracts
Publicado: (2022)